Melanoma-associated markers expression in blood: MUC-18 is associated with advanced stages in melanoma patients

British Journal of Dermatology

Volumn 160, Issue 2, 2009, Pages 338-344

  Rapanotti, M C ^a   Bianchi, L ^b   Ricozzi, I ^b   Campione, E ^b   Pierantozzi, A ^a   Orlandi, A ^b   Chimenti, S ^b   Federici, G ^a,c   Bernardini, S ^a,c  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

American Joint Committee on Cancer (AJCC) stages; MUC 18; Multimarker reverse transcriptase polymerase chain reaction assay

Indexed keywords

CD146 ANTIGEN; MELAN A; MELANOMA ANTIGEN 3; MESSENGER RNA; PROTEIN P97; TYROSINE;

ADULT; AGED; ARTICLE; BLOOD; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

ADULT; AGED; ANTIGENS, CD146; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 58349103909     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08929.x     Document Type: Article

References (43)

1. Balch CM, Soong SJ, Milton GW et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982 196 : 677 84.
2. Clark WC, Elder DE, Van Horn M. The biologic forms of malignant melanoma. Hum Pathol 1986 17 : 443.
3. Armstrong BK, English DR. Cutaneous malignant melanoma. In : Cancer Epidemiology and Prevention (Schottenfeld D, Fraumeni JF Jr., eds 2nd edn. New York : Oxford University Press, 1996 1282 312.
4. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001 15 : 3635 48.
5. Hoon DSB, Wang Y, Dale PS et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995 13 : 2109 16.
6. Orlow SJ, Hearing HJ, Sakai C. Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Proc Natl Acad Sci USA 1995 92 : 10152 6.
7. Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment and recurrence from melanoma. J Clin Oncol 1998 16 : 1760 9.
8. Reynolds SR, Albrecht J, Shapiro RL et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003 9 : 1497 502.
9. Scolyer RA, Thomson JF, Stretch JR et al. Pathology of melanocytic lesions: new, controversial and clinically important issues. J Surg Oncol 2004 86 : 200 11.
10. Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumour cells in solid tumors. Clin Cancer Res 1999 5 : 1950.
11. Max N, Keilholz U. Minimal residual disease in melanoma. Sem Surg Oncol 2001 20 : 319 28.
12. Smith B, Selby P, Southgate J et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991 338 : 1227 9.
13. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastase. J Clin Oncol 1999 17 : 2562 71.
14. Mellado B, Gutierrez L, Castel T et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 1999 5 : 1843 8.
15. Palmieri G, Strazzullo M, Ascierto PA et al. Polymerase chain reaction-based detection circulating melanoma cells as an effective marker of tumor progression. J Clin Oncol 1999 17 : 304 11.
16. Schittek B, Bodingbauer Y, Ellwanger U et al. Amplification of Melan A messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br J Dermatol 1999 141 : 30 6.
17. Aubin F, Chtourou M, Teyssier JR et al. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Res 2000 10 : 113 18.
18. Palmieri G, Ascierto PA, Perrone F et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003 21 : 767 73.
19. Washer RA, Morton DL, Kuo C et al. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol 2003 21 : 2558 63.
20. Martinez SR, Hoon DSB. Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony? J Cell Biochem 2005 96 : 473 83.
21. Tsao H, Nadiminti U, Sober AJ et al. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol 2001 137 : 325 30.
22. Brownbridge GG, Gold J, Edward M, Mackie RM. Evaluation of the use of tyrosinase-specific and MelanA/MART-1-specific reverse transcriptase-coupled- polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol 2001 144 : 279 87.
23. Elder DE, Murphy GF. Melanocytic Tumors of the Skin, 3rd edn. Washington, DC : Armed Forced Institute of Pathology Edns, 1996.
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987 162 : 156 9.
25. Ghossein RA, Rosai J. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer 1996 78 : 10 16.
26. Hanekom GS, Stubbings HM, Johnson CA, Kidson SH. The detection of circulating melanoma cells correlates with tumour thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. Melanoma Res 1999 9 : 465 73.
27. Hoon DSB, Bostick P, Kuo C. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000 60 : 2253 7.
28. Luca M, Hunt B, Bucana CD et al. Direct correlation between MUC-18 expression and metastatic potential of human melanoma cells. Melanoma Res 1993 3 : 35 41.
29. Xie S, Luca M, Huang S et al. Expression of MCAM/MUC 18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 1997 57 : 2295 303.
30. Holzmann B, Brocker EB, Lehmann JM et al. Tumor progression in human melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 1987 39 : 466 71.
31. Lehmann JM, Holzmann B, Breitbart EW et al. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 1987 47 : 841 5.
32. Lehmann JM, Riethmuller G, Johnson JP. MUC 18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad SCI USA 1989 86 : 9891 5.
33. Satyamoorthy K, Muyrers J, Meier F et al. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene 2001 20 : 4676 84.
34. Mills L, Tellez C, Huang S et al. Fully human antibodies to MCAM/MUC 18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002 62 : 5106 14.
35. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970 172 : 902 8.
36. Liu W, Dowling JP, Murray WK et al. Rate of growth in melanomas. Arch Dermatol 2006 142 : 1551 8.
37. Pacifico MD, Grover R, Richman PI et al. Development of tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 2005 115 : 367 75.
38. Melnikova VO, Bar-Eli M. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC 18 and IL-8. Pigment Cell Res 2006 19 : 395 405.
39. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 1995 346 : 1334 5.
40. Hu X, Loo WTY, Chow LWC. Surgery-related shedding of breast cancer cells as determined by RT-PCR assay. J Surg Oncol 2003 82 : 228 32.
41. Morton DE, Essner R, Kirkwood JM, Parker RG. Malignant melanoma. In : Cancer Medicine (Holland JF, Frei E III., Kufe DW, Morton DL, Weichselbaum RR, eds). Baltimore, MD : Williams & Wilkins, 1998 2467 99.
42. Palmieri G, Satriano SMR, Budroni M et al. Serial detection of circulating tumor cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer 2006 6 : 266 74.
43. Schuster R, Bechrakis NE, Stroux A et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary melanoma. Clin Cancer Res 2007 13 : 1171 8.